TransMedics Group, Inc. (TMDX)
NEUTRALFundamental
67
Kurs
$93.27
Marktkapitalisierung
$3.26B
Teil 1 · Was das Unternehmen wert ist
Übersicht
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$668M
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$152M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$134M
Gesamtes Eigenkapital
$473M
Gesamtverbindlichkeiten
$595M
Current Ratio
6.62
Zinsdeckungsgrad
3.84
Schulden/EBITDA
6.39
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$78.14
Aktueller Kurs
$93.27
Sicherheitsmarge
-19.4%
Innerer-Wert-Spanne
$50.79 - $105.49
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
24.25
ROE
40.2%
P/B-Verhältnis
6.26
P/FCF
41.06
Bruttomarge
58.7%
ROIC
4.7%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
4.7%
WACC
12.3%
ROIC − WACC
-7.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (17)
- EPS shows upward trend
- Price CAGR 25.79%
- Gross Margin 58.7%
- Debt/Equity ratio
- Operating Margin 12.2%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 33.0%
- Revenue Growth 5Y 88.2%
- Analyst Consensus 68% Buy
- Earnings Surprise avg 14.1%
- Earnings Quality (OCF/NI) 0.96
- Net Margin Trend 22.7% vs 13.5%
- Piotroski F-Score 7/9
Nicht bestanden (8)
- ROIC 4.7%
- P/FCF 41.06
- P/B Ratio 6.26
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 11.3%
Nicht verfügbar (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Mittel: Gewisse Differenz zwischen Gewinn und Cashflow
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Waleed H. Hassanein M.D. | Founder, President, CEO & Director | 57 |
| Mr. Gerardo Hernandez | CFO & Treasurer | 54 |
| Mr. Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | 43 |
| Dr. Tamer I. Khayal M.D. | Senior Vice President of International | 56 |
| Mr. Anil Ranganath | Advisor | 43 |
| Mr. Matthew Forsyth | Senior VP, General Counsel & Corporate Secretary | - |
| Ms. Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs | 64 |
Prüfungsrisiko
10
Vorstandsrisiko
3
Vergütungsrisiko
7
Aktionärsrechterisiko
3
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for TMDX, sourced from Markets Gazette.
- 3/8/2026POSITIVETransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026?
TransMedics Group Inc. has demonstrated remarkable growth, with its stock price surging 104% over the past year. The company is recognized for its innovative approach to revolutionizing the organ transplant industry. Despite this impressive performance, market sentiment remains divided, with some analysts labeling the stock as 'overvalued.' Investors are now contemplating whether the significant gains made thus far leave room for further appreciation by 2026, balancing the company's disruptive potential against current valuation concerns.
- 2/28/2026POSITIVEGot $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot
TransMedics Group, Inc., a mid-cap healthcare specialist, is drawing investor attention as a potential 'moonshot' in the high-tech organ transplant sector. The company, focused on advanced solutions for organ preservation and transport, is seen as a significant investment opportunity for those seeking growth in innovative medical fields. Analysts suggest that with an initial capital of around $5,000, investors might consider a deeper look into this company, given its prominent position in a market segment with high expansion potential and technological innovation. Its technology could revolutionize current practices, offering attractive long-term return prospects.
via Markets Gazette